Compare IHT & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IHT | CYCN |
|---|---|---|
| Founded | 1971 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2M | 16.6M |
| IPO Year | 1995 | 2019 |
| Metric | IHT | CYCN |
|---|---|---|
| Price | $1.30 | $3.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.2K | ★ 36.0K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | N/A | ★ 8.26 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,600,000.00 | $2,074,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.33 | ★ 3.70 |
| 52 Week Low | $0.95 | $1.03 |
| 52 Week High | $4.24 | $8.48 |
| Indicator | IHT | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 29.68 | 58.67 |
| Support Level | $1.26 | $2.93 |
| Resistance Level | $1.51 | $4.47 |
| Average True Range (ATR) | 0.13 | 0.38 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 13.27 | 56.17 |
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns interests in two hotels, operates and provides management services, and provides trademark license services, for two hotels. The Trust also holds an investment related to clean energy electricity generation technology and manages an option to acquire an investment in an independent boutique hotel reservation and hotel services business.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.